Due to the indispensable role of this family in controlling glioma TME, we constructed a 4‐chemokine prognostic signature and explored the relationship between this gene signature and the immune‐related landscape as well as the anti‐PD‐1 therapeutic responses. The gene discussed is PDCD1; the disease is central nervous system cancer.